Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Prostatic Neoplasms 48Breast Neoplasms 8Neoplasms 4Leiomyoma 3Breast Neoplasms, Male 2Sexual Dysfunction, Physiological 1Prostate Adenocarcinoma 1Neoplasm Metastasis 1Myofibroma 1Breast Cancer Invasive 1Advanced Prostate Cancer 1Advanced Prostate Adenocarcinoma 1Adenocarcinoma 1

Interventions

exemestane 4Tamoxifen 3Paclitaxel 3Letrozole 3Goserelin 3Cyclophosphamide 3pegfilgrastim 2Radiotherapy 2Pyridoxine 2Leuprolide 2Fluorouracil 2Epirubicin 2Capecitabine 2Bevacizumab 2Anastrozole 2trastuzumab biosimilar HLX02 1ribociclib 1elacestrant 1Zoledronic Acid 1Trastuzumab 1Taxes 1Radiosurgery 1Prochlorperazine 1Palonosetron 1PF-05280014 1Ontruzant 1Ogivri 1Neoadjuvant Therapy 1Mometasone Furoate 1Methotrexate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Breast Neoplasms, Male × Leuprolide × Clear all
NCT05827081 2026-06-03

Adjuvant WIDER

Novartis

Phase 3 Recruiting
1,400 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT01674140 2026-02-10

e3

SWOG Cancer Research Network

Phase 3 Active not recruiting
1,939 enrolled 15 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡